Inclusion Criteria:

- Signed written informed consent

- Male or female subjects aged greater than or equal to 18 years

- Histologically or cytologically proven metastatic or locally advanced solid tumors,
for which no standard therapy exists or standard therapy has failed

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry
and an estimated life expectancy of at least 3 months

- Disease must be measurable with at least 1 uni-dimensional measurable lesion by
RECIST 1.1

- Adequate hepatic function as defined in the protocol

- Adequate renal function defined by an estimated creatinine clearance greater than 50
milliliter per minute (mL/min) according to the Cockcroft-Gault formula

- Effective contraception for both male and female subjects if the risk of conception
exists

- Other inclusion criteria apply

Exclusion Criteria:

- Concurrent treatment with a non-permitted drug

- Prior therapy with specific antibody/drug targeting T cell co-regulatory proteins
(immune checkpoints)

- Concurrent anticancer treatment concurrent systemic therapy with steroids or other
immunosuppressive agents, or use of any investigational drug within 30 days before
the start of trial treatment. Short-term administration of steroids (that is, for
allergic reactions or the management of immune-related adverse events [irAE]) is
allowed

- Previous malignant disease within the last 5 years with the exception of basal or
squamous cell carcinoma of the skin or cervical carcinoma in situ

- Pregnancy or lactation period

- Known alcohol or drug abuse

- Clinically significant (that is, active) cardiovascular disease

- All other significant diseases (for example, inflammatory bowel disease), which, in
the opinion of the investigator, might impair the subject's tolerance of trial
treatment

- Any psychiatric condition that would prohibit the understanding or rendering of
informed consent

- Legal incapacity or limited legal capacity

- Other exclusion criteria apply